The American Heart Association and Verily, with support from AstraZeneca, collectively committed $75 million over at least five years to support a groundbreaking research idea aimed at preventing or reversing coronary heart disease and, ultimately, improving and restoring cardiovascular health.
In addition to the funding, representatives from the from American Heart Association, Verily and AstraZeneca, who form the One Brave Idea Joint Leadership Group, pledged to provide guidance, mentorship and substantial resources to bring the winning research idea to fruition.
Dr. Calum MacRae, chief of cardiovascular medicine at Brigham and Women’s Hospital in Boston, and his world-class team were selected as the recipients of the $75 million One Brave Idea research award. The team plans to lead an innovative research effort focused on preventing or reversing coronary heart disease.
The AHA, Verily, and AstraZeneca have each committed $25 million and the vast resources of their organizations as they partner with Dr. MacRae and his worldwide team of interdisciplinary leaders. These experts will seek to develop precise methods to detect coronary heart disease at its very earliest stages, long before its symptoms have had a chance to fully manifest themselves.
"We're no longer going to wait for a patient to show up with complaints or symptoms or something we recognize as a problem," Dr. MacRae said. "We're going to actively go out and look for their problems earlier and earlier, and find the most fundamental mechanisms of the disease."
Dr. MacRae, who was chosen from a pool of nearly 350 outstanding applicants from 22 countries, is Chief of Cardiology at Boston's Brigham and Women's Hospital.
"Dr. MacRae has an extraordinary grasp of very, very different sorts of science and the type of expertise that needs to be brought to the table," said Dr. Robert Harrington, a member of the One Brave Idea Selection Committee and Chair of the Department of Medicine at the Stanford University School of Medicine.
Congratulations to Dr. MacRae and his incredible team, and thank you to each and every one of our applicants for submitting their inspiring, novel ideas which have given One Brave Idea the potential to become the new paradigm for studying diseases.